Navigation Links
Cambrex Reports Fourth Quarter and Full Year 2009 Results
Date:2/10/2010

/p>

Fourth quarter 2009 sales of $58.7 million were 9.9% lower than the fourth quarter 2008.  Excluding a 5.9% favorable impact of foreign exchange, reflecting a weaker U.S. dollar, sales decreased 15.8%.  The decrease is primarily due to lower volumes of an active pharmaceutical ingredient ("API") that utilizes the Company's polymeric drug delivery technology, lower sales of two APIs manufactured under long-term supply agreements and lower custom development revenues, all due to the timing of orders throughout 2009.  Volumes of a feed additive for which a contract expired earlier in 2009 were also lower.  Partially offsetting these decreases were increased generic revenues resulting from improved order patterns.

Fourth quarter 2009 Gross Margin increased to 24.7% of sales from 24.2% during the fourth quarter 2008, with foreign currency unfavorably impacting gross margin by 0.6% in the fourth quarter 2009.  Cost reductions, and to a lesser extent, positive product mix, were the main drivers of the higher margins.  This was partially offset by lower pricing of generic APIs and lower volumes of an API manufactured under a long-term supply agreement.

Selling, General and Administrative Expenses in the fourth quarter 2009 were $8.8 million compared to $9.0 million in the same period last year.  The decrease is a result of lower personnel costs and professional fees at the corporate headquarters and the benefit of the termination of certain postretirement benefits partially offset by higher legal fees, higher expenses at the Company's manufacturing sites and an unfavorable impact of foreign currency.

Research and Development Expenses increased to $2.0 million in the fourth quarter 2009 from $1.6 million in the fourth quarter 2008 due to high
'/>"/>

SOURCE Cambrex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. Cambrex Presentation at the JPMorgan Healthcare Conference to be Webcast
2. Cambrex to Announce Fourth Quarter and Full Year 2007 Financial Results on February 14, 2008
3. Cambrex Appoints Steven M. Klosk as President and CEO
4. Cambrex Reports Third Quarter 2008 Results
5. Cambrex Receives Notice Regarding NYSE Listing
6. Cambrex Reports First Quarter 2009 Results
7. Cambrex Continuous-Flow Microwave-Assisted Organic Synthesis Technology Nominated for 2009 Innovations Award
8. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
9. QMed, Inc. Reports July Medicare SNP Enrollments
10. Phlo Affiliate Reports Expanded Coverage to Oregon Border
11. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/23/2014)... VEGAS , July 23, 2014  GrowBLOX Sciences, Inc. ... today that it is filing for two medical marijuana dispensary ... locations are in addition to the Clark County, ... a special use permit, as previously announced.  GrowBLOX ... to be submitting two new applications for dispensaries in the ...
(Date:7/23/2014)... 23, 2014 a2z Inc. announces that ... App, AACC Pathfinder, in its 2014 Annual Meeting ... meeting is planned for July 29-31, 2014 in Chicago, ... be to connect with global leaders in clinical chemistry, ... other areas of breaking science in laboratory medicine. , ...
(Date:7/22/2014)... D.C., June 22, 2014 Even within a phylum so ... is distinguished among other arthropods for its cruelty -- at ... Central America, the fly is a most predatory sort of ... cricket, deposits a smear of larvae, and leaves its wicked ... out. , None of this would be possible without ...
(Date:7/22/2014)... July 22, 2014 Nuclear reactors are ... produced by controlled fission chain reaction in nuclear reactors ... is used to drive a power- generating turbine. Currently ... the world’s total electricity production. Nuclear reactor market is ... construction, planned and proposed nuclear reactor projects. , Early ...
Breaking Biology Technology:GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 2GrowBLOX Sciences, Inc. Files for Two Additional Medical Marijuana Dispensaries in Las Vegas 3AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 2AACC Enhances Attendee Experience at Its 2014 Annual Meeting & Clinical Lab Expo with a2z-Powered ChirpE Photo Booth and Mobile App 3Fly-inspired sound detector 2Fly-inspired sound detector 3Fly-inspired sound detector 4Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 2Nuclear Energy Market: Global Industry Analysis, Size, Share, Analysis, Growth and Forecast 2013 - 2019 3
... Calif., March 20, 2012 Cepheid (NASDAQ: ... of Medicine and Dentistry of New Jersey (UMDNJ), it ... Health to develop sample processing and amplification methods for ... reaction (PCR) on the GeneXpert® System. The $1.3 million ...
... March 20, 2012 Heptares Therapeutics, the ... company of Shire PLC (LSE: SHP, NASDAQ: ... its exclusive option to license a novel adenosine A ... in preclinical development. Adenosine A 2A is a ...
... 19, 2012  MiMedx Group, Inc. (OTCBB: MDXG), an ... regenerative biomaterials and bioimplants processed from human amniotic ... distribution agreement with Systagenix, whereby Systagenix will co-market ... specifically processed from amniotic tissue, EpiFix® offers a ...
Cached Biology Technology:Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria 2Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria 3Cepheid Receives Grant to Develop Sample Processing and Amplification Methods for Detection of Bloodstream Bacteria 4Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders 2Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders 3MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix® 2MiMedx Signs Agreement with Systagenix for Global Distribution of EpiFix® 3
(Date:7/23/2014)... strength, but it also holds the promise of a ... to convert sunlight into a clean, efficient alternative fuel. ... group using spinach to study the proteins involved in ... energy into carbohydrates used to power cellular processes. , ... efficient system ever built, capable of converting the energy ...
(Date:7/23/2014)... Migratory songbirds are disappearing, and though conservationists are examining ... habitat, acid rain and light pollution, a key piece ... birds go once they leave their breeding sites, and ... , To answer this question, a team of researchers ... migratory connectivity map produced for a songbird, using tracking ...
(Date:7/23/2014)... planet,s soil releases about 60 billion tons of carbon ... than that released by burning fossil fuels. This happens ... of carbon is balanced by carbon coming into the ... as well as by the underground activities of plant ... rising temperatures increase the rate of soil respiration. As ...
Breaking Biology News(10 mins):Spinach could lead to alternative energy more powerful than Popeye 2York University researchers use bird 'backpacks' to put wood thrushes migration on the map 2Climate change and the soil 2
... 2012) Aeras and the Infectious Disease Research Institute ... trial of IDRI,s novel tuberculosis vaccine candidate, ID93 + ... safety, tolerability and immunogenicity of the vaccine candidate in ... by Johnson County Clin-Trials in Lenexa, Kansas, in close ...
... has on pregnancy, are urging men to get ... development. Reproductive experts from the University of ... father,s obesity negatively impacts sperm, resulting in smaller ... While the health risks surrounding obesity ...
... Venture has developed a framework to evaluate the risk ... A paper based on this work: A framework for ... has been published in the Malaria Journal ... anti-infective drug, so it is important when developing new ...
Cached Biology News:As TB grows more difficult to control, vaccine candidate to prevent disease enters clinical testing 2Thinking about kids? Man, you gotta shed the kilos 2MMV develops framework to assess risk of resistance for antimalarial compounds 2